Document is current
Any future updates will be listed below
-
Authors
Shah, Jaynish S.
Milevskiy, Michael J. G.
Petrova, Veronika
Au, Amy Y. M.
Wong, Justin J. L.
Visvader, Jane E.
Schmitz, Ulf
Rasko, John E. J.
-
Funding
Funding for this research was provided by:
Victorian Cancer Agency
National Health and Medical Research Council, Australia (1196405, 1177305)
Cancer Council NSW (RG20-12, RG11-12)
- License Information
-
More Information
Article History
Received: 10 July 2022
Accepted: 12 December 2022
First Online: 29 December 2022
Declarations
:
: Not applicable.
: Not applicable.
: J.E.J.R. has received honoraria or speaker fees (GSK, Miltenyi, Takeda, Gilead, Pfizer, Spark, Novartis, Celgene, bluebird bio); Director of Pathology (Genea); equity ownership (Genea, Rarecyte); consultant (Rarecyte, Imago); and chair, Gene Technology Technical Advisory, OGTR, Australian Government. The remaining authors declare no competing financial interests.
